InvestorsHub Logo
Followers 22
Posts 1557
Boards Moderated 0
Alias Born 01/23/2014

Re: None

Wednesday, 07/24/2019 11:17:17 PM

Wednesday, July 24, 2019 11:17:17 PM

Post# of 2676
Topline Results Expected in the Third Quarter of 2019

Enrollment is complete in BELIEVE 1, an open label multi-dose Phase 2 clinical trial evaluating the efficacy and safety of Zygel in children and adolescents (three through 17 years) with DEE. The primary efficacy assessment is reduction in seizure frequency at week 26 compared to baseline. The Company expects to announce topline data through week 26 in the third quarter of 2019.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ZYNE News